Introduction – A Historic Step in Type 1 Diabetes Care
On 14 August 2025, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved Teplizumab (Tzield) – the first-ever treatment proven to delay the progression of type 1 diabetes by an average of three years.
This comes after the U.S. FDA first approved Teplizumab in November 2022, making it available in the United States for patients aged 8 years and above with stage 2 type 1 diabetes.
At Dr. Raj Diabetes Centre, we believe our patients in India deserve to know about such global breakthroughs in type 1 diabetes prevention and care.
What is Teplizumab?
Teplizumab is a first-in-class immunotherapy for people at stage 2 type 1 diabetes (positive autoimmune markers + abnormal blood sugars, but no insulin requirement yet).
Key facts about Teplizumab:
- Type of drug: Humanized anti-CD3 monoclonal antibody
- How it works: Protects pancreatic beta cells by calming the immune system
- Dosage: 14-day course of daily IV infusions
- Eligibility: People aged 8 years and above with stage 2 type 1 diabetes
How Does Teplizumab Work?
In type 1 diabetes, the immune system attacks the insulin-producing beta cells.
Teplizumab targets the root cause by:
- Reducing immune attack on beta cells
- Preserving the body’s ability to make insulin
- Slowing the onset of stage 3 diabetes and insulin dependence
Clinical results:
Patients on Teplizumab saw an average delay of 3 years before needing insulin compared to those without the drug.
Why This is a Global Breakthrough
Until now, there was no approved medicine to delay type 1 diabetes progression.
Teplizumab:
- Gives patients more healthy years without insulin
- Reduces complications linked to early blood sugar spikes
- Improves quality of life for families and children at risk
Teplizumab Approval Timeline
- US FDA Approval: November 2022
- UK MHRA Approval: 14 August 2025 (first in Europe)
- India: Not yet approved – pending regulatory process
What Does This Mean for Patients in India?
Teplizumab is not yet available in India, but its success highlights the importance of:
- Early screening for type 1 diabetes risk in families with a history of the condition
- Regular monitoring for autoimmune antibodies and abnormal glucose levels
- Patient education so eligible individuals can benefit once approved here
At Dr. Raj Diabetes Centre, we offer advanced screening and monitoring to detect early signs of type 1 diabetes.
Key Benefits of Teplizumab
- Delays insulin use by ~3 years
- Protects beta cells from autoimmune destruction
- Improves early-stage outcomes in type 1 diabetes
- One-time 14-day treatment can have long-lasting benefits
Next Steps for Indian Patients
While waiting for Indian approval, families should:
- Ask about type 1 diabetes risk testing
- Maintain healthy lifestyle habits to reduce stress on beta cells
- Stay updated on global research via trusted sources like Dr. Raj Diabetes Centre
Final Thoughts
Teplizumab represents a new era in type 1 diabetes care – shifting from only managing symptoms to preventing progression.
Our clinic will continue tracking developments and will work to bring such innovations to patients in India as soon as possible.
References:
- UK MHRA Official Announcement (14 Aug 2025)
- U.S. FDA Approval Notice (Nov 2022)
- Diabetes UK Guidance